Elisabeth Pedersen1, Beate Hennie Garcia2, Kjell H Halvorsen2, Anne Elise Eggen3, Henrik Schirmer4,5, Marit Waaseth2. 1. Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway. elisabeth.pedersen@uit.no. 2. Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway. 3. Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway. 4. Department of Cardiology, Akershus University Hospital, Lørenskog, Norway. 5. Institute of Clinical Medicine Campus Ahus, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: Adherence to clinical practice guidelines for coronary heart disease (CHD) reduces morbidity, mortality and treatment costs. We aimed to describe and compare adherence to prescription guidelines for persons with CHD, and explore its association with treatment goal achievement. METHOD: We included all participants reporting myocardial infarction, angina, percutaneous coronary intervention and/or coronary artery bypass surgery in the seventh wave of the Tromsø Study (2015-2016, n = 1483). Medication use and treatment goal measures (blood pressure, low-density lipoprotein (LDL)-cholesterol and HbA1c) were compared to clinical practice guidelines on secondary CHD prevention. Propensity score matched logistic regression was used to assess the association between the use of antihypertensive drugs and achievement of treatment goal for blood pressure, and the use of lipid-lowering drugs (LLDs) and achievement of treatment goal for LDL-cholesterol. RESULTS: The prevalence of pharmacological CHD treatment was 76% for LLDs, 72% for antihypertensive drugs and 66% for acetylsalicylic acid. The blood pressure goal (< 140/90 mmHg, < 140/80 mmHg if diabetic) was achieved by 58% and the LDL-cholesterol goal (< 1.8 mmol/l or < 70 mg/dL) by 9%. There was a strong association between using LLDs and achieving the treatment goal for LDL-cholesterol (OR 14.0, 95% CI 3.6-54.7), but not between using antihypertensive drugs and blood pressure goal achievement (OR 1.4, 95% CI 0.7-2.7). CONCLUSION: Treatment goal achievement of LDL-cholesterol and blood pressure was low, despite the relatively high use of LLDs and antihypertensive drugs. Further research is needed to find the proper actions to increase achievement of the treatment goals.
BACKGROUND: Adherence to clinical practice guidelines for coronary heart disease (CHD) reduces morbidity, mortality and treatment costs. We aimed to describe and compare adherence to prescription guidelines for persons with CHD, and explore its association with treatment goal achievement. METHOD: We included all participants reporting myocardial infarction, angina, percutaneous coronary intervention and/or coronary artery bypass surgery in the seventh wave of the Tromsø Study (2015-2016, n = 1483). Medication use and treatment goal measures (blood pressure, low-density lipoprotein (LDL)-cholesterol and HbA1c) were compared to clinical practice guidelines on secondary CHD prevention. Propensity score matched logistic regression was used to assess the association between the use of antihypertensive drugs and achievement of treatment goal for blood pressure, and the use of lipid-lowering drugs (LLDs) and achievement of treatment goal for LDL-cholesterol. RESULTS: The prevalence of pharmacological CHD treatment was 76% for LLDs, 72% for antihypertensive drugs and 66% for acetylsalicylic acid. The blood pressure goal (< 140/90 mmHg, < 140/80 mmHg if diabetic) was achieved by 58% and the LDL-cholesterol goal (< 1.8 mmol/l or < 70 mg/dL) by 9%. There was a strong association between using LLDs and achieving the treatment goal for LDL-cholesterol (OR 14.0, 95% CI 3.6-54.7), but not between using antihypertensive drugs and blood pressure goal achievement (OR 1.4, 95% CI 0.7-2.7). CONCLUSION: Treatment goal achievement of LDL-cholesterol and blood pressure was low, despite the relatively high use of LLDs and antihypertensive drugs. Further research is needed to find the proper actions to increase achievement of the treatment goals.
Authors: John Munkhaugen; Elise Sverre; Jan E Otterstad; Kari Peersen; Erik Gjertsen; Joep Perk; Lars Gullestad; Torbjørn Moum; Toril Dammen; Einar Husebye Journal: Eur J Prev Cardiol Date: 2017-02-14 Impact factor: 7.804
Authors: Bjørn Gjelsvik; Anh Thi Tran; Tore J Berg; Åsne Bakke; Ibrahimu Mdala; Kjersti Nøkleby; John G Cooper; Tor Claudi; Karianne Fjeld Løvaas; Geir Thue; Sverre Sandberg; Anne K Jenum Journal: BJGP Open Date: 2019-03-20
Authors: Jan Mannsverk; Tom Wilsgaard; Ellisiv B Mathiesen; Maja-Lisa Løchen; Knut Rasmussen; Dag S Thelle; Inger Njølstad; Laila Arnesdatter Hopstock; Kaare Harald Bønaa Journal: Circulation Date: 2015-11-18 Impact factor: 29.690
Authors: Elise Sverre; Kari Peersen; Einar Husebye; Erik Gjertsen; Lars Gullestad; Torbjørn Moum; Jan Erik Otterstad; Toril Dammen; John Munkhaugen Journal: BMC Cardiovasc Disord Date: 2017-01-21 Impact factor: 2.298
Authors: Laila A Hopstock; Anne Elise Eggen; Maja-Lisa Løchen; Ellisiv B Mathiesen; Amalie Nilsen; Inger Njølstad; Tom Wilsgaard Journal: Open Heart Date: 2018-01-03
Authors: Piotr Jankowski; Paweł Kozieł; Grzegorz Bilo; Jarosław Pinkas; Danuta Czarnecka; Kalina Kawecka-Jaszcz; Andrzej Pająk Journal: Int J Hypertens Date: 2022-08-05 Impact factor: 2.434